Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 11/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14377785 | 0.90 | ALK (0.42) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14377777 | 0.90 | PDPK1 (0.44) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14378015 | 0.90 | TTK (0.45) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14378027 | 0.90 | PDPK1 (0.44) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14377790 | 0.90 | TTK (0.43) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14378019 | 0.89 | PDPK1 (0.43) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14377792 | 0.89 | TTK (0.44) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14335962 | 0.88 | TTK (0.43) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14377775 | 0.88 | TTK (0.42) | TTKCLK1CLK2ALKPDPK1 | |
| SCHEMBL14378033 | 0.88 | PDPK1 (0.42) | TTKCLK1CLK2ALKPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723736-B1 | 7-Azaindole derivatives suitable for the treatment of cancers | MERCK PATENT GMBH (DE) | 2015-08-05 | — | — | EP | claimed |
| US-8993564-B2 | 7-azaindole derivatives suitable for treatment of cancers | MERCK PATENT GMBH (DE) | 2015-03-31 | — | — | US | claimed |
| US-20140187551-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | MERCK PATENT GMBH (DE) | 2014-07-03 | — | — | US | claimed |
| EP-2723736-B1 | 7-Azaindole derivatives suitable for the treatment of cancers | MERCK PATENT GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2723736-B1 | 7-Azaindole derivatives suitable for the treatment of cancers | MERCK PATENT GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-8993564-B2 | 7-azaindole derivatives suitable for treatment of cancers | MERCK PATENT GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-8993564-B2 | 7-azaindole derivatives suitable for treatment of cancers | MERCK PATENT GMBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-20140187551-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | MERCK PATENT GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187551-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | MERCK PATENT GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| WO-2012175168-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | MERCK PATENT GMBH (DE) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187551-A1 | 7-AZAINDOLE DERIVATIVES SUITABLE FOR TREATMENT OF CANCERS | PDK1, PDK2, PDK3 | TTK 922/4885CLK1 1510/4885CLK2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.